Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.